HypercholesterolemiaNCT05082350
Nutritional Intervention With Black Garlic
A study testing black garlic in people with Hypercholesterolemia and Hypertension, run by Maria Pilar Zafrilla Rentero at 1 site in Spain.
Trial summary
A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Read more about this study
- Who is it for?
- Ages 40 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypercholesterolemia, Hypertension, Hyperlipidemias
- What is being tested?
- black garlic
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 1 siteSpain
- Study dates
- 1 Sep 2020to 30 Nov 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Group:
- Total blood cholesterol levels of less than 200 mg/dL
- LDL-cholesterol levels of less than 135 mg/dL
- Not suffer from any other pathology.
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.
- Cardiovascular Risk Group:
Show all 10Show fewer
- Total cholesterol levels between 200-300 mg/dL
- LDL-cholesterol levels between 135-175 mg/dL.
- No acute or chronic pathology, except hypercholesterolemia
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.).
Who cannot join
- Failure to meet any of the inclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Trial to Evaluate the Efficacy of Black Garlic in Reducing Cardiovascular Risk in Subjects With Hypercholesterolemia
A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.
Read the detailed description
A parallel, controlled clinical trial will be performed to assess the effect of garlic on mild hypercholesterolemia.
The study will conducted in two groups of volunteer: healthy and at cardiovascular risk (hypercholesterolemic subjects), consuming black garlic, with each individual acting as its own control. The study will have a total duration of 18 weeks, divided in two stages:
- Stage 1: basal or washout stage of 2 weeks, in which volunteer follow their usual diet with restrictions
- Stage 2: intervention stage of 16 weeks, in which volunteer consume black garlic Sixty healthy volunteers (men and women) between 40-65 years old and BMI between 24.9-29.9 kg/m2 will be recruited. From the total of volunteer, 30 will correspond to the Healthy Group, which should have total blood cholesterol levels less than 200 mg/dL and LDL-cholesterol less than 135 mg/dL.
The other 30 volunteers correspond to the Cardiovascular Risk Group, which should have total cholesterol levels between 200-300 mg/dL and LDL-cholesterol levels between 135-175 mg/dL.
Other inclusion criteria established for all volunteers are: no acute or chronic pathology, (except hypercholesterolemia for the risk group), no taking drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism.
The study has been approved by the Ethical Committee of Catholic University of Murcia (UCAM) and will be carried out in accordance with the Helsinki Declaration of Human Studies. Recruitment will take place at various Health Centers and at UCAM. All participants will be informed on the characteristics of the study and, after signing the informed consent, a routine analysis will be requested to classify the volunteer in the healthy or cardiovascular risk group.
To avoid bias due to gender, the number of women and men recruited in both groups will be balanced. The size of the study population has been estimated taking total blood cholesterol level as the main variable and taking into account that the study design is randomized and parallel. Considering a statistical power of 80%, a statistical significance level of 5% (one tail), a standard deviation of 6.5, aiming to estimate a difference of 2.5, the number of volunteers required is 25 for each group, rising to 30 in anticipation of dropouts. This number, being two study groups, will allow obtaining results with statistical significance in other biochemical parameters that would be determined as secondary variables of the study and that would inform on the effect of black garlic consumption on cardiovascular function and associated dysfunctions (inflammation, hypertension, endothelial function, diabetes, etc.).
After an initial washout (basal) stage common to all groups, in which the volunteers will consume their usual diet with restriction in the consumption of fresh garlic and garlic products, the intervention will start, with the consumption of black garlic for 12 weeks. Volunteers will be provided with black garlic and they will ensure that no other type of garlic or culinary seasoning is used.
Dietary and physical activity questionnaire according to the "Global Physical Activity Questionnarie (GPAQ)" will be compiled in order to collect information on habits and lifestyle, as well as to ensure the compliance of food restrictions.
During the study, visits will be scheduled on the first day and last day of each stage. The subjects will come to the Unit on fasting conditions and will provide the first morning urine. Blood sample will be taken, plasma aliquoted and stored at -80°C until analysis.
- Conditions
- Hypercholesterolemia, Hypertension, Hyperlipidemias, Inflammation, Endothelial Dysfunction
- Being tested
- black garlic
- Keywords
- black garlic, sulphur bioactive compounds, hypercholesterolemia, hyperlipemia, inflammation, endothelial dysfunction
- Medical subject headings
- Hypercholesterolemia, Hypertension, Hyperlipidemias, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
black garlicDietary supplement
Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Healthy Group, | Experimental | Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks Receives: Dietary Supplement: black garlic |
| Hypercholesterolemia | Experimental | Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks Receives: Dietary Supplement: black garlic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Impact on blood pressure
Blood pressure (diastolic, systolic)
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Impact on lipid profile
Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B.
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Secondary outcomes (9)
Impact on blood cells (Hematology)
Blood counts
Measured: changes observed from baseline at day 0 compared to 12 weeks.
evaluation of liver function to determine product safety
Hepatic enzymes (GOT, GPT)
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Changes in cytokine levels
Plasma levels of pro-inflammatory: IL-1β, IL6 , TNF-α (tumor necrosis factor) and anti-inflammatory (IL-10, IL-17) cytokines.
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Changes in chemokine MCP-1 (monocyte chemotactic protein)
Plasma levels of chemokine MCP-1
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Changes in C reactive protein
Plasma levels of C reactive protein
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Impact on endothelial function
Plasma levels of nitric oxide, adhesion molecules VCAM-1 (vascular endothelial cell adhesion molecule), ICAM-1 (intercellular adhesion molecule), chemokines as markers of endothelium (E-selectin) and platelet (P-selectin) activation.
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Impact on glucose levels
Plasma levels of glucose
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Impact on glycosylated hemoglobin (HbA1c)
Plasma levels of glycosylated hemoglobin
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Impact in hormones related to metabolism
Plasma levels of thyroid hormones (TSH, T3, T4).
Measured: changes observed from baseline at day 0 compared to 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Oct 2021
- Study start1 Sep 2020
- Primary completion30 Jun 2021
- Study completion30 Nov 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease.
- Masking
- None (open label)
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maria Pilar Zafrilla Rentero
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto de Investigación y formación agraria y pesquera (IFAPA)
- Responsible party
- Sponsor-investigator, Maria Pilar Zafrilla Rentero, Catholic University of Murcia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05082350
- Sponsor's protocol ID
- CFE/IF/28-20
- Status last verified
- Oct 2021
- First submitted
- 8 Jun 2021
- Last updated
- 18 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Trial to Evaluate the Efficacy of Black Garlic in Reducing Cardiovascular Risk in Subjects With Hypercholesterolemia
- ClinicalTrials.gov ID
- NCT05082350
- Acronym / sponsor ID
- CFE/IF/28-20
- Conditions
- Hypercholesterolemia, Hypertension, Hyperlipidemias, Inflammation, Endothelial Dysfunction
- Keywords
- black garlic, sulphur bioactive compounds, hypercholesterolemia, hyperlipemia, inflammation, endothelial dysfunction
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Maria Pilar Zafrilla RenteroUniversity, hospital or other
- Collaborators
- Instituto de Investigación y formación agraria y pesquera (IFAPA)
- Study start
- 1 Sep 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 30 Nov 2021 (estimated)
- First posted
- 18 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.
Detailed description
A parallel, controlled clinical trial will be performed to assess the effect of garlic on mild hypercholesterolemia.
The study will conducted in two groups of volunteer: healthy and at cardiovascular risk (hypercholesterolemic subjects), consuming black garlic, with each individual acting as its own control. The study will have a total duration of 18 weeks, divided in two stages:
- Stage 1: basal or washout stage of 2 weeks, in which volunteer follow their usual diet with restrictions
- Stage 2: intervention stage of 16 weeks, in which volunteer consume black garlic Sixty healthy volunteers (men and women) between 40-65 years old and BMI between 24.9-29.9 kg/m2 will be recruited. From the total of volunteer, 30 will correspond to the Healthy Group, which should have total blood cholesterol levels less than 200 mg/dL and LDL-cholesterol less than 135 mg/dL.
The other 30 volunteers correspond to the Cardiovascular Risk Group, which should have total cholesterol levels between 200-300 mg/dL and LDL-cholesterol levels between 135-175 mg/dL.
Other inclusion criteria established for all volunteers are: no acute or chronic pathology, (except hypercholesterolemia for the risk group), no taking drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism.
The study has been approved by the Ethical Committee of Catholic University of Murcia (UCAM) and will be carried out in accordance with the Helsinki Declaration of Human Studies. Recruitment will take place at various Health Centers and at UCAM. All participants will be informed on the characteristics of the study and, after signing the informed consent, a routine analysis will be requested to classify the volunteer in the healthy or cardiovascular risk group.
To avoid bias due to gender, the number of women and men recruited in both groups will be balanced. The size of the study population has been estimated taking total blood cholesterol level as the main variable and taking into account that the study design is randomized and parallel. Considering a statistical power of 80%, a statistical significance level of 5% (one tail), a standard deviation of 6.5, aiming to estimate a difference of 2.5, the number of volunteers required is 25 for each group, rising to 30 in anticipation of dropouts. This number, being two study groups, will allow obtaining results with statistical significance in other biochemical parameters that would be determined as secondary variables of the study and that would inform on the effect of black garlic consumption on cardiovascular function and associated dysfunctions (inflammation, hypertension, endothelial function, diabetes, etc.).
After an initial washout (basal) stage common to all groups, in which the volunteers will consume their usual diet with restriction in the consumption of fresh garlic and garlic products, the intervention will start, with the consumption of black garlic for 12 weeks. Volunteers will be provided with black garlic and they will ensure that no other type of garlic or culinary seasoning is used.
Dietary and physical activity questionnaire according to the "Global Physical Activity Questionnarie (GPAQ)" will be compiled in order to collect information on habits and lifestyle, as well as to ensure the compliance of food restrictions.
During the study, visits will be scheduled on the first day and last day of each stage. The subjects will come to the Unit on fasting conditions and will provide the first morning urine. Blood sample will be taken, plasma aliquoted and stored at -80°C until analysis.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease.
| Arm | Type | Receives |
|---|---|---|
| Healthy Group, | Experimental | Dietary Supplement: black garlicDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks |
| Hypercholesterolemia | Experimental | Dietary Supplement: black garlicDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Total blood cholesterol levels of less than 200 mg/dL
- LDL-cholesterol levels of less than 135 mg/dL
- Not suffer from any other pathology.
- No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.
- Total cholesterol levels between 200-300 mg/dL
Key exclusion criteria (1 listed)
- Failure to meet any of the inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| black garlicDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks | Dietary supplement | Healthy Group,, Hypercholesterolemia |
Primary outcome
Impact on blood pressure
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Blood pressure (diastolic, systolic)
Impact on lipid profile
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B.
9 secondary outcomes
Impact on blood cells (Hematology)
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
evaluation of liver function to determine product safety
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Changes in cytokine levels
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Changes in chemokine MCP-1 (monocyte chemotactic protein)
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Changes in C reactive protein
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Impact on endothelial function
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Impact on glucose levels
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Impact on glycosylated hemoglobin (HbA1c)
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Impact in hormones related to metabolism
Time frame: changes observed from baseline at day 0 compared to 12 weeks.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2021.
- Individual participant dataSharing planned: No
Related trials for Hypercholesterolemia
RecruitingObservational study
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Hypercholesterolemia, Dyslipidemias
RecruitingPhase 3
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing black garlic in people with Hypercholesterolemia and Hypertension, run by Maria Pilar Zafrilla Rentero at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Impact on blood pressure (time frame: changes observed from baseline at day 0 compared to 12 weeks.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2021.